Do analysts recommend RDY or SUPN?

Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 44.34%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Supernus Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media favor RDY or SUPN?

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or SUPN?

In the previous week, Lantheus and Lantheus both had 6 articles in the media. Lantheus' average media sentiment score of 1.34 beat Supernus Pharmaceuticals' score of 1.03 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or SUPN?

In the previous week, Belite Bio had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Belite Bio and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Belite Bio's score of 0.81 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LQDA or SUPN?

In the previous week, Liquidia had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Liquidia's score of 0.64 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 5 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Supernus Pharmaceuticals (SUPN) Competitors

$43.53 -0.44 (-1.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

SUPN vs. RDY, CRNX, LNTH, BLTE, and LQDA

Should you buy Supernus Pharmaceuticals stock or one of its competitors? Supernus Pharmaceuticals's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Lantheus (LNTH), Belite Bio (BLTE), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 44.34%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Dr. Reddy's Laboratories has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.79	$456M	$0.44	27.20
Supernus Pharmaceuticals	$718.95M	3.52	-$38.55M	-$1.92	N/A

Summary

Supernus Pharmaceuticals beats Dr. Reddy's Laboratories on 11 of the 17 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Supernus Pharmaceuticals' return on equity of 11.13% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Supernus Pharmaceuticals currently has a consensus target price of $62.83, suggesting a potential upside of 44.34%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Supernus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.52	-$38.55M	-$1.92	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

In the previous week, Crinetics Pharmaceuticals had 12 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Crinetics Pharmaceuticals and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Crinetics Pharmaceuticals' score of 0.69 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Supernus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Lantheus and Lantheus both had 6 articles in the media. Lantheus' average media sentiment score of 1.34 beat Supernus Pharmaceuticals' score of 1.03 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 7.07%. Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 44.34%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Lantheus has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39
Supernus Pharmaceuticals	$718.95M	3.52	-$38.55M	-$1.92	N/A

Lantheus has a net margin of 17.69% compared to Supernus Pharmaceuticals' net margin of -13.23%. Lantheus' return on equity of 28.10% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Lantheus beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Belite Bio had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Belite Bio and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Belite Bio's score of 0.81 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Belite Bio currently has a consensus price target of $214.64, indicating a potential upside of 10.86%. Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 44.34%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Belite Bio has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Supernus Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Supernus Pharmaceuticals	$718.95M	3.52	-$38.55M	-$1.92	N/A

Summary

Supernus Pharmaceuticals beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Liquidia has a net margin of 30.74% compared to Supernus Pharmaceuticals' net margin of -13.23%. Liquidia's return on equity of 149.65% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Supernus Pharmaceuticals has higher revenue and earnings than Liquidia. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	13.63	-$68.92M	$1.37	50.12
Supernus Pharmaceuticals	$718.95M	3.52	-$38.55M	-$1.92	N/A

Liquidia has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 42.85%. Supernus Pharmaceuticals has a consensus target price of $62.83, indicating a potential upside of 44.34%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Liquidia had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Liquidia's score of 0.64 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.5% of Liquidia shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Liquidia beats Supernus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.56B	$12.29B	$7.28B	$12.92B
Dividend Yield	N/A	2.58%	2.53%	8.90%
P/E Ratio	-22.67	787.21	272.43	25.42
Price / Sales	3.52	793.46	634.35	95.42
Price / Cash	11.65	92.18	77.39	52.28
Price / Book	2.45	12.47	12.85	6.17
Net Income	-$38.55M	$2.82B	$3.48B	$349.50M
7 Day Performance	-0.46%	3.91%	0.99%	-0.15%
1 Month Performance	-7.21%	6.17%	5.49%	1.02%
1 Year Performance	-5.37%	9.88%	24.34%	14.50%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	4.5207 of 5 stars	$43.53 -1.0%	$62.83 +44.3%	-4.2%	$2.56B	$718.95M	N/A	580	Positive News
RDY Dr. Reddy's Laboratories	1.607 of 5 stars	$12.20 +0.5%	N/A	-15.4%	$10.18B	$3.58B	27.72	27,527
CRNX Crinetics Pharmaceuticals	1.4445 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	News Coverage Positive News Analyst Forecast High Trading Volume
LNTH Lantheus	3.9249 of 5 stars	$101.00 +0.0%	$108.11 +7.0%	+87.6%	$6.59B	$1.54B	24.39	1,193	Positive News
BLTE Belite Bio	2.3671 of 5 stars	$155.10 -0.4%	$205.80 +32.7%	+197.2%	$6.25B	N/A	N/A	10	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. RDY, CRNX, LNTH, BLTE, and LQDA

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. RDY, CRNX, LNTH, BLTE, and LQDA

How does Supernus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Do analysts recommend RDY or SUPN?

Which has more risk & volatility, RDY or SUPN?

Does the media favor RDY or SUPN?

Is RDY or SUPN more profitable?

Do insiders & institutionals believe in RDY or SUPN?

Which has higher valuation & earnings, RDY or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Is SUPN or CRNX more profitable?

Which has more volatility and risk, SUPN or CRNX?

Do insiders & institutionals hold more shares of SUPN or CRNX?

Do analysts prefer SUPN or CRNX?

Which has better earnings and valuation, SUPN or CRNX?

Does the media favor SUPN or CRNX?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Does the media prefer LNTH or SUPN?

Do insiders and institutionals have more ownership in LNTH or SUPN?

Do analysts prefer LNTH or SUPN?

Which has better earnings and valuation, LNTH or SUPN?

Is LNTH or SUPN more profitable?

Which has more volatility & risk, LNTH or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Do insiders & institutionals believe in BLTE or SUPN?

Does the media prefer BLTE or SUPN?

Which has more volatility and risk, BLTE or SUPN?

Do analysts prefer BLTE or SUPN?

Is BLTE or SUPN more profitable?

Which has higher earnings and valuation, BLTE or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Is LQDA or SUPN more profitable?

Which has higher valuation & earnings, LQDA or SUPN?

Which has more risk and volatility, LQDA or SUPN?

Do analysts recommend LQDA or SUPN?

Does the media prefer LQDA or SUPN?

Do insiders and institutionals believe in LQDA or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools